SMARCA4 and neoplasm: Our findings demonstrate that, in contrast to SCLC (8), both xenografts of SMARCA4-mutant cell lines previously classified as SCLC-Y and patient-derived primary SMARCA4-UT tumor samples show diffuse, uniformly strong YAP1 protein staining.